Alnylam Pharmaceuticals vs Eleven Therapeutics
Alnylam Pharmaceuticals vs Eleven Therapeutics, compared side by side on 13 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Alnylam Pharmaceuticals is on 19/100 and Eleven Therapeutics on 56/100.
Where each one leads
Alnylam Pharmaceuticals
- domain rating: 72/100 against 13/100
Eleven Therapeutics
- our overall score: 56/100 against 19/100
At a glance
| Measure | Alnylam Pharmaceuticals | Eleven Therapeutics |
|---|---|---|
| What it is | Biopharmaceutical company pioneering RNA interference (RNAi) therapeutics to treat rare and prevalent genetic diseases. | Israeli-UK biotech company developing novel RNA therapeutics for rare genetic diseases. |
| Category | Biotechnology, Pharmaceuticals, Healthcare | Healthcare, Life Sciences, Therapeutics, Biotech |
| Sells toBusiness model | B2B | B2B |
| Offering | Services | Platform |
| Founded | 2002 | 2017 |
| Headquarters | Cambridge, United States | London, United Kingdom |
| Status | Active | Active |
Size, funding and growth
| Measure | Alnylam Pharmaceuticals | Eleven Therapeutics |
|---|---|---|
| Employees | Not published | 28 |
| Headcount growthLast 12 months | Not published | +17.6% |
| Open roles | Not published | 4 |
| Total funding | Not published | $22.0M |
| Latest round | Not published | Seed |
| LinkedIn followers | Not published | 5,528 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Alnylam Pharmaceuticals | Eleven Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 19/100 | 56/100 |
| Traction | Not published | 51/100 |
| Team | 70/100 | 70/100 |
| Search visibility | 11/100 | 30/100 |
| Quality | Not published | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (42/100) | D (40/100) |
| Domain ratingLink authority, 0-100 | 72/100 | 13/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Alnylam Pharmaceuticals | Eleven Therapeutics |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CDN | Not detected | Cloudflare |
| CMS | Not detected | Webflow |
| Frameworks | Jquery, Bootstrap | Not detected |
| Open source | Yes | No |
Alnylam Pharmaceuticals vs Eleven Therapeutics: common questions
Which is better, Alnylam Pharmaceuticals or Eleven Therapeutics?
On our 0-100 score Eleven Therapeutics rates higher (56/100 against 19/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 13 data points above: read the rows that match what you are buying for.
How do Alnylam Pharmaceuticals and Eleven Therapeutics compare on the numbers?
Alnylam Pharmaceuticals leads on domain rating (72/100 against 13/100). Eleven Therapeutics leads on our overall score (56/100 against 19/100).
Read the full Alnylam Pharmaceuticals review and pricing or the Eleven Therapeutics review and pricing. You can also browse other Alnylam Pharmaceuticals alternatives we track.